GlobeNewsWire
25 Aug 2026, 18:50 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Sionna Therapeutics reported a primary endpoint miss in its PreciSION CF Phase 2a trial. — Missing a primary endpoint in a clinical trial typically suggests a failure of the drug's efficacy, severely damaging the company's valuation.
-0.90Sionna Therapeutics will not advance SION-719 as an add-on to standard of care. — The abandonment of a key pipeline candidate removes a significant future revenue driver and asset from the company's portfolio.
-0.80The Law Offices of Frank R. Cruz is investigating Sionna Therapeutics for possible violations of federal securities laws. — Legal investigations into securities fraud create additional liability and governance risk, though usually secondary to the clinical failure.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company missed a primary trial endpoint, halted a drug candidate, saw its stock price crash by 91.2%, and is under investigation for securities fraud.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
